UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C.  20549 

 

FORM 8-K



CURRENT REPORT 

  

  Pursuant to Section 13 or 15(d)
      

  of the Securities Exchange Act of 1934




Date of Report (Date of earliest event reported):  April 8, 2008

Protalix BioTherapeutics, Inc.


(Exact name of registrant as specified in its charter)


Florida

(State or other jurisdiction of incorporation)


  
     
     
     
  
  
    000-27836

      (Commission File Number) 
     
    65-0643773

      (IRS Employer Identification No.)
  



2 Snunit Street
    

  Science Park
  

  POB 455
  

  Carmiel, Israel 20100


(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +972-4-988-9488
(Former Name or Former Address, if Changed Since Last Report)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):




    o
     
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



     


    o
     
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



     


    o
     
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



     


    o
     
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 



 
 
 
 








Item 8.01. Other Events
On April 8, 2008, the Company issued a press release announcing that it has been awarded a grant of up to approximately $4 million by the Office of the Chief Scientist of Israel’s Ministry of Industry and Trade. The Office of the Chief Scientist has awarded this grant to the Company for the advancement of the Company’s clinical and preclinical drug development programs.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits


 
        
                        
(d)
 
        
                        
Exhibits 
  



 
        
                        
99.1
 
        
                        
Press release dated April 8, 2008
  

 
 
2
 
 




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


 
        
                        
 
 
        
                        
 
 
        
                        
PROTALIX BIOTHERAPEUTICS, INC.
  
 
        
                        

 Date: April 9, 2008
 
        
                        
 
 
        
                        
By: 
 
        
                        

 /s/ David Aviezer
  
 
        
                        
 
 
        
                        
 
 
        
                        
Name:      
 
        
                        
David Aviezer, Ph.D.
  
 
        
                        
 
 
        
                        
 
 
        
                        
Title:
 
        
                        
President and
 Chief Executive Officer
  

 
 
3